.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical research examines the impact of SGLT-2 inhibitors cancer risk among individuals living with type 2 diabetes. This large-scale retrospective cohort study compared patients starting sodium-glucose co-transporter 2 inhibitors (SGLT-2i) with those initiating dipeptidyl peptidase-4 inhibitors (DPP-4i). By utilizing real-world data from the TriNetX US Collaborative Network, investigators aimed to determine if these glucose-lowering agents influence obesity-associated malignancies.
Notably, the initiation of SGLT-2 inhibitors did not show a significant association with composite obesity-associated cancers compared to DPP-4i. However, the study revealed distinct findings for specific cancer types within the overall population. For instance, SGLT-2i users experienced a 22% lower rate of renal cancer. Conversely, researchers observed a 37% higher rate of thyroid cancer in the same group. Consequently, these findings suggest that the relationship between drug class and malignancy is nuanced and site-specific.
Furthermore, the analysis demonstrated modest reductions in the all-cancer outcome for the overall diabetic population. This trend remained consistent among individuals regardless of their overweight or obesity status. While the clinical significance of these overall reductions remains unclear, the potential for protective effects against certain tumors is an area for future investigation. Therefore, clinicians must balance metabolic benefits with long-term safety profiles when selecting second-line therapies.
In conclusion, while SGLT-2 inhibitors appear safe regarding the broad category of obesity-related cancers, the observed variations in renal and thyroid cancer rates warrant attention. This real-world evidence provides a deeper understanding of how modern diabetes medications interact with oncological risks in high-risk populations.
No, this large-world study found that SGLT-2 inhibitors were not associated with higher or lower rates of composite obesity-associated cancers when compared with DPP-4 inhibitors.
The study reported a lower rate of renal cancer (HR 0.78) but identified a higher rate of thyroid cancer (HR 1.37) in patients initiating SGLT-2 inhibitors compared to those on DPP-4 inhibitors.
Yes, researchers noted a modest reduction in the all-cancer outcome among the general cohort and those with overweight or obesity who initiated SGLT-2 inhibitors.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional opinion. Readers should consult with a qualified healthcare professional regarding any medical concerns or treatments. Refer to the latest local and national guidelines for clinical practice.
References
Ipaye T et al. Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study. Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70562. PMID: 41749411.
Zheng J et al. Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025 Aug 07.
Wang Y et al. Impact of SGLT2 Inhibitors on Tumor Development Risk in Type 2 Diabetes. Drug Des Devel Ther. 2025 Dec 15.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A retrospective cohort study finds SGLT-2 inhibitors are not linked to overall obesity-associated cancers but show varying effects on renal and thyroid risk...
5 months ago
A Bayesian network meta-analysis evaluated non-surgical treatments for benign thyroid nodules, finding thermal ablation techniques like laser and radiofrequency ablation superior in nodule volume reduction, whereas levothyroxine showed the strongest TSH suppression without significant changes in FT3 or FT4.
Today
A retrospective study demonstrates that deep learning models using longitudinal digital breast tomosynthesis significantly enhance 5-year breast cancer risk prediction compared to single-timepoint imaging and clinical models.
Today
Researchers developed poly(trimethylene carbonate)-based polymersomes loaded with L-arginine for ROS-triggered nitric oxide release. This mild, stable nano-delivery system produces gas in response to hydrogen peroxide, offering a promising, targeted platform for cardiovascular, surgical, and oncological therapy.
Today
Researchers developed a Haversian-inspired composite scaffold that addresses delayed vascularization and wet-state mechanical deterioration in critical bone defect repair. By integrating spatially programmed calcium phosphate minerals and selective silica reinforcement, the design promotes vascularized bone repair.
Yesterday
A landmark study analyzing over 56,000 adult health records in Delhi-NCR reveals that hypertension and diabetes coexistence affects nearly 5% of adults. The prevalence doubles expected rates and rises sharply after age 40. Early integrated screening is essential to prevent microvascular and macrovascular complications.
Today
